Clinical specialists commonly generate a
karyotype to examine the chromosomes of
cancer cells or for amniocentesis in prenatal diagnosis, which has a much lower resolution than Array CGH, said Michael Teitell, a researcher with the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and the senior author of the study.
However, most human solid tumors have an abnormal
karyotype implying that gain and loss of chromosomes by
cancer cells confers a selective advantage.